Our results may explain the low autologous MSCT efficacy for severe refractory SLE patients [20], and inhibition of TNF-α pathway could promote BMSCs migration to the inflammatory microenvironment in SLE patients, thereby having a potential role in SLE treatment. This evidence concerns the gene TNF and systemic lupus erythematosus.